Related Experiment Video
Updated: May 9, 2026
10:21
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
[CEBPA gene mutation analysis in acute myeloid leukemia]
Cong Han1, Dong Lin, Xiao-fei Ai
1Institute of Hematology and Blood diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|August 3, 2013
Summary
CCAAT/enhancer binding protein alpha (CEBPA) gene mutations occur in 15% of acute myeloid leukemia (AML) patients, correlating with specific clinical features and a higher complete remission rate. These CEBPA mutations can serve as a marker for minimal residual disease.
Area of Science:
- Hematology
- Molecular Biology
- Genetics
Background:
- Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
- Genetic mutations play a crucial role in AML pathogenesis and prognosis.
- CCAAT/enhancer binding protein alpha (CEBPA) is a key transcription factor implicated in myeloid differentiation.
Purpose of the Study:
- To determine the incidence, molecular characteristics, and clinical significance of CEBPA gene mutations in de novo AML.
- To evaluate the utility of CEBPA mutations as a biomarker for minimal residual disease (MRD) monitoring.
- To explore the relationship between CEBPA mutations and other genetic alterations, such as NPM1 mutations.
Main Methods:
- Mutation analysis of the entire coding region of the CEBPA gene in 206 de novo AML patients.
- Utilized polymerase chain reaction (PCR) followed by sequence and fragment length analysis.
- Dynamic tracking of CEBPA mutations during complete remission and relapse.
Main Results:
- CEBPA gene mutations were identified in 15% (31/206) of AML patients, with 23 having double mutations (duCEBPA) and 8 having single mutations (siCEBPA).
- CEBPA mutations were associated with higher white blood cell counts, higher hemoglobin levels, lower platelet counts, and were prevalent in M2 subtype and intermediate-risk patients.
- Patients with CEBPA mutations showed a significantly higher complete remission (CR) rate compared to those with wild-type CEBPA. CEBPA mutations disappeared at CR and reappeared at relapse, indicating their potential as MRD markers. NPM1 mutations were absent in duCEBPA cases but present in some siCEBPA cases within the M5 subtype.
Conclusions:
- CEBPA gene mutation is a recurrent genetic alteration in AML with significant correlations to clinical and laboratory features.
- CEBPA mutations are valuable markers for monitoring minimal residual disease in AML patients.
- The prognostic impact of co-occurring siCEBPA and NPM1 mutations in AML-M5 subtype warrants further investigation.
